Pharma BD Deal Intelligence
Took 9 years to reach the US market and 13 to become the global standard of care, but CINtec ultimately delivered on the cervical-cancer-testing thesis — just never as a disclosed, scaled revenue line.
Full analysis, sources & comparables →mtm products are highly complementary to Roche's innovative cobas HPV assay, creating a comprehensive cervical cancer testing portfolio from cytological…
Roche acquires mtm laboratories, broadening cervical cancer testing capabilities; mtm products are highly complementary to Roche's cobas HPV assay, giving a…
Roche extends cervical cancer diagnostics franchise via €190M acquisition of mtm laboratories, gaining p16 biomarker IP that complements its molecular HPV…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Roche/Ventana acquired German cervical-cancer diagnostics specialist mtm laboratories for €130M upfront (~$184M) plus up to €60M (~$85M) in milestones; total up to ~$269M. Complemented Roche's cobas HPV cervical screening platform.
Took 9 years to reach the US market and 13 to become the global standard of care, but CINtec ultimately delivered on the cervical-cancer-testing thesis — just never as a disclosed, scaled revenue line.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / mtm laboratories AG (this deal) | 2011 | $269M | 65 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2011 deals · Roche Holding AG deals · Oncology deals